Frontier IP Group Plc, through its subsidiaries, identifies and evaluates commercialization of intellectual property generated by academics, universities, and other partners in the United Kingdom. It also provides investment advisory and marketing services. The company was incorporated in 2007 and is based in London, the United Kingdom.

Frontier IP Group Plc

Frontier IP Group Plc focuses on commercialising intellectual property from research, utilizing expertise in various fields to co-found and develop innovative businesses.

Frontier IP Group plc | 922 followers on LinkedIn. We build value by uniting science, industry and finance to commercialise university intellectual property | Frontier IP specialises in the commercialisation of 
Intellectual Property (IP).
 
Frontier IP establishes partnerships with individual universities and research institutions to assist with their spin-out and licensing activities and help maximise the commercial value of technologies emerging from their research programmes.
 
Frontier IP Group plc is quoted on the AIM market.

Independent Non-Executive Director

Nigel Grierson

Chief Commercialisation Officer at Frontier IP Group plc

Matthew White

Wilson BioPharma Consulting

Campbell Wilson

Finance Director at Frontier IP Group plc

Jim Fish

Frontier IP Group plc

The Vaccine Group and the UK government's Animal and Plant Health Agency have been awarded an Innovate UK Smart grant to develop vaccines against two commercially damaging cattle diseases. Watch TVG CEO Dr Jeremy Salt discuss the project and other developments at the company. #brsv #lumpyskindisease TVG #animalhealth https://lnkd.in/eH2BQ5hj

Great to see our portfolio company The Vaccine Group partnering with the UK government's Animal and Plant Health Agency. They have been awarded an Innovate UK Smart grant to develop cattle vaccines. Initial target diseases are bovine respiratory syncytial virus (BRVS) and lumpy skin disease. Both cause significant economic damage to beef and dairy farmers worldwide. You can learn more here: https://lnkd.in/eHGdMk4q #iuk #innovateuk #brsv #lumpyskindisease #apha #defra

Watch The Vaccine Group CEO Jeremy Salt discuss how a UK government grant will help the company and its partners at the University of Plymouth and the University of Cambridge tackle a bacterial disease in pigs that can also prove fatal in humans. https://lnkd.in/e5vSs-7F #streptococcus #tvg #zoonotic

Our portfolio company The Vaccine Group has teamed up with the University of Plymouth and the University of Cambridge to develop a vaccine to combat a widespread, economically harmful and zoonotic pig disease, which can be fatal to humans. Streptococcus suis is a bacterial infection which is endemic in the global pig population. It can cause meningitis and sceptacaemia in humans. The project is being supported by a grant of more than £1 million from Defra 's Farming Innovation Programme, delivered by Innovate UK. #innovateUK #defra #streptococcus #vaccines #tvg https://lnkd.in/e45pFxRE

We are delighted that Nesta Impact Investments, the investment arm of UK social innovation agency Nesta, has supported our portfolio company Nandi Proteins. Nesta #foodingredients #innovation https://lnkd.in/e7RviH6g

Watch Pulsiv Chief Product Officer Dr Tim Moore discuss the potential for the company's groundbreaking technology with Proactive's Stephen Gunnion: https://lnkd.in/gfC9YkMX #usbc #energyefficiency #pulsiv Proactive Oakglen Wealth Tim tells Proactive’s Stephen Gunnion about the groundbreaking technology behind its latest release—the world’s most efficient 65-watt USB-C reference design charger. Moore detailed how Pulsiv’s focus on maximising power conversion efficiency has led to a cooler-running, more reliable charging solution. He emphasised that the charger’s design, which significantly reduces inrush current, ensures both the safety and longevity of the product, making it ideal for in-socket applications. Tim also discussed the broader market potential, especially as new EU regulations make USB-C connectors mandatory across a wide range of devices. Pulsiv’s technology not only supports these evolving standards but also positions itself as a key player in the fast-growing fast-charger market. As Tim explained, consumers are likely to demand faster charging times across various cordless products, driving the need for high-power USB-C supplies like Pulsiv’s 65W charger. In addition to USB-C applications, Moore hinted at future advancements in AC to DC conversion, which could impact sectors like solar power generation. The conversation highlights Pulsiv’s innovative approach to power conversion, promising a safer and more efficient future for electronic devices.

Listen to Pulsiv chairman Mark Gerhard explain why he thinks the company is Arm 2.0 at an Oakglen Wealth Invest in Innovation seminar earlier this year: https://lnkd.in/gUyzq7Gs Pulsiv has launched the world's most efficient 65W USB-C charger reference design. The ground-breaking technology promises to expand and open up new markets for the USB-C fast charging global standard because it enables operation at much lower temperatures, minimizes energy loss as power is converted, and reduces the size of critical components. But Pulsiv's underlying technology can be used much more widely, to improve the efficiency of power conversion across a host of different applications. It can also boost output from solar cells. #usbc #energyefficiency

Our portfolio company Pulsiv is today launching the world's most efficient 65W USB-C reference design. The ground-breaking technology promises to expand and open up new markets for the USB-C fast charging global standard because it enables operation at much lower temperatures, minimizes energy loss as power is converted, and reduces the size of critical components. #pulsiv #usb -c #energyefficiency https://lnkd.in/eGrYDFeA

	Jun '14	Jun '15	Jun '16	Jun '17	Jun '18	Jun '19	Jun '20	Jun '21	Jun '22	Jun '23
revenue	178K -	170K 4.49%	221K 30%	264K 19.46%	299K 13.26%	418K 39.80%	404K 3.35%	362K 10.40%	329K 9.12%	372K 13.07%
cost of revenue	464K -	583K 25.65%	592K 1.54%	690K 16.55%	879K 27.39%	1.28M 45.16%	1.45M 13.32%	1.53M 6.09%	1.71M 11.73%	1.52M 11.44%
gross profit	-286K -	-413K 44.41%	-371K 10.17%	-426K 14.82%	-580K 36.15%	-858K 47.93%	-1.04M 21.45%	-1.17M 12.48%	-1.39M 18.17%	-1.15M 17.26%
selling and marketing expenses	25K -	25K 0%	18K 28.00%	32K 77.78%	54K 68.75%	56K 3.70%	22K 60.71%	1K 95.45%	7K 600%
general and administrative expenses	769K -	945K 22.89%	900K 4.76%	1.08M 20.22%	1.47M 35.40%	1.93M 31.88%	418K 78.36%	498K 19.14%	522K 4.82%	695K 33.14%
selling general and administrative expenses	769K -	945K 22.89%	900K 4.76%	1.08M 20.22%	1.47M 35.40%	1.93M 31.88%	418K 78.36%	498K 19.14%	522K 4.82%	695K 33.14%
research and development expenses
other expenses	18K -	44K 144.44%	48K 9.09%	91K 89.58%	150K 64.84%	257K 71.33%	27K 89.49%	403K 1,392.59%	2.70M 570.97%
cost and expenses	769K -	945K 22.89%	900K 4.76%	1.08M 20.22%	1.47M 35.40%	1.93M 31.88%	2.21M 14.60%	2.44M 9.98%	3.23M 32.48%	3.27M 1.43%
operating expenses	769K -	945K 22.89%	900K 4.76%	1.08M 20.22%	1.47M 35.40%	1.93M 31.88%	768K 60.25%	2.44M 217.06%	1.51M 37.91%	1.75M 16.01%
interest expense									1K -
ebitda	-1.20M -	-2.19M 83.14%	-2.49M 13.40%	-2.86M 15.07%	-3.23M 12.82%	-5.36M 66.07%	-7.78M 44.99%	-14.37M 84.81%	-16.66M 15.94%	-1.14M 93.16%
operating income	-559K -	646K 215.56%	1.13M 74.92%	1.23M 8.58%	898K 26.81%	2.34M 160.36%	4.16M 78.06%	10.23M 145.81%	10.88M 6.30%	-4.42M 140.63%
depreciation and amortization	1K -	2K 100%	2K 0%	2K 0%	5K 150%	6K 20%	6K 0%	6K 0%	8K 33.33%	9K 12.50%
total other income expenses net	586K -	1.41M 140.96%	1.80M 27.55%	2.04M 13.55%	2.05M 0.34%	3.86M 88.30%	5.99M 55.12%	12.31M 105.46%	-2.87M 123.27%	50K 101.74%
income before tax	27K -	647K 2,296.30%	1.13M 74.81%	1.23M 8.66%	902K 26.61%	2.35M 160.53%	4.18M 78.04%	10.24M 144.79%	10.88M 6.22%	-4.37M 140.17%
income tax expense	-640K -	-1.43M 123.59%	-1.82M 27.18%	-2.05M 12.58%	2.05M 200.15%	-3.86M 287.91%	-5.97M 54.90%	676K 111.32%	649K 3.99%	-1.13M 273.50%
net income	27K -	647K 2,296.30%	1.13M 74.81%	1.23M 8.66%	902K 26.61%	2.35M 160.53%	4.18M 78.04%	9.57M 128.63%	10.23M 6.94%	-3.24M 131.71%
weighted average shs out	20.09M -	23.41M 16.54%	27.72M 18.40%	32.98M 18.98%	38.28M 16.05%	40.70M 6.33%	47.75M 17.33%	54.76M 14.68%	55.01M 0.45%
weighted average shs out dil	20.38M -	23.85M 17.07%	28.00M 17.37%	33.90M 21.07%	40.11M 18.34%	42.63M 6.28%	49.78M 16.75%	57.55M 15.62%	58.34M 1.38%
eps	0.00 -	0.03 2,023.08%	0.04 47.83%	0.04 8.58%	0.02 36.73%	0.06 144.49%	0.09 51.82%	0.17 94.06%	0.19 11.76%	0 100%
epsdiluted	0.00 -	0.03 1,984.62%	0.04 49.08%	0.04 10.15%	0.02 38.02%	0.06 144.89%	0.08 52.63%	0.17 102.14%	0.18 5.88%	0 100%

FIPP

UK:CO:FRONTIERIP

Frontier IP Group Plc

Last Close

29.00

25/11 09:23

Market Cap

194.56K

Beta: -

Volume Today

49.24K

Avg: -

Preview